Dr. Jacqueline Lui, Managing Director of Eagle IP Limited, and Dr. H.C. Lui, Director of Eagle IP Limited, participated the Israel-Asia Summit 2013 in Israel, with the S.T.A.R.S. Foundation delegation.
我們過去活動
Recommended Insights
Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data
2025年4月1日“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]
閱讀更多 >
China Top 50 Case of 2019: How a Functional Feature is Construed Greatly Impacts Protection Scope - Shimano KK v. SENSAH
2020年7月20日Every year in the spring The Supreme People’s Court of PRC announces its “Top 10 Intellectual Property (IP) cases” and “50 typical IP cases in Chinese courts” of the year. Although not having precedential weight, these cases serve as a reference and guide people's courts at all levels regarding their intellectual property trials. It’s always […]
閱讀更多 >
When Standards Evolve: How China Judges Inventiveness in Next-Gen Tech Patents
2025年9月30日Starting in 2023, Datang Mobile, one of the key players in China’s telecom standardization efforts, initiated infringement proceedings against Samsung in China, Germany, and the US. Samsung responded by filing multiple invalidation petitions in several jurisdictions, including China, the United States, and Europe. The case discussed below is one of above-mentioned invalidation cases in China, […]
閱讀更多 >
Is it Sufficient to Claim an Antibody only by Describing its Antigen?
2018年11月12日Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]
閱讀更多 >